150 related articles for article (PubMed ID: 19176983)
1. Effects of the phosphodiesterase type 4 inhibitor roflumilast on early and late allergic response and airway hyperresponsiveness in Aspergillus-fumigatus-sensitized mice.
Hoymann HG; Wollin L; Muller M; Korolewitz R; Krug N; Braun A; Beume R
Pharmacology; 2009; 83(3):188-95. PubMed ID: 19176983
[TBL] [Abstract][Full Text] [Related]
2. Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats.
Chapman RW; House A; Jones H; Richard J; Celly C; Prelusky D; Ting P; Hunter JC; Lamca J; Phillips JE
Eur J Pharmacol; 2007 Oct; 571(2-3):215-21. PubMed ID: 17610865
[TBL] [Abstract][Full Text] [Related]
3. Suppression of cytokine expression by roflumilast and dexamethasone in a model of chronic asthma.
Herbert C; Hettiaratchi A; Webb DC; Thomas PS; Foster PS; Kumar RK
Clin Exp Allergy; 2008 May; 38(5):847-56. PubMed ID: 18307529
[TBL] [Abstract][Full Text] [Related]
4. Surfactant protein D inhibits early airway response in Aspergillus fumigatus-sensitized mice.
Erpenbeck VJ; Ziegert M; Cavalet-Blanco D; Martin C; Baelder R; Glaab T; Braun A; Steinhilber W; Luettig B; Uhlig S; Hoymann HG; Krug N; Hohlfeld JM
Clin Exp Allergy; 2006 Jul; 36(7):930-40. PubMed ID: 16839409
[TBL] [Abstract][Full Text] [Related]
5. Effects of ciclamilast, a new PDE 4 PDE4 inhibitor, on airway hyperresponsiveness, PDE4D expression and airway inflammation in a murine model of asthma.
Deng YM; Xie QM; Tang HF; Sun JG; Deng JF; Chen JQ; Yang SY
Eur J Pharmacol; 2006 Oct; 547(1-3):125-35. PubMed ID: 16956605
[TBL] [Abstract][Full Text] [Related]
6. Ovalbumin-sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation.
Zosky GR; Larcombe AN; White OJ; Burchell JT; Janosi TZ; Hantos Z; Holt PG; Sly PD; Turner DJ
Clin Exp Allergy; 2008 May; 38(5):829-38. PubMed ID: 18070158
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge.
Louw C; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbroker D; Bardin PG
Respiration; 2007; 74(4):411-7. PubMed ID: 16954654
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors.
Wollin L; Bundschuh DS; Wohlsen A; Marx D; Beume R
Pulm Pharmacol Ther; 2006; 19(5):343-52. PubMed ID: 16257550
[TBL] [Abstract][Full Text] [Related]
9. Effect of roflumilast on airway remodelling in a murine model of chronic asthma.
Kim SW; Kim JH; Park CK; Kim TJ; Lee SY; Kim YK; Kwon SS; Rhee CK; Yoon HK
Clin Exp Allergy; 2016 May; 46(5):754-63. PubMed ID: 26542330
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma.
Kumar RK; Herbert C; Thomas PS; Wollin L; Beume R; Yang M; Webb DC; Foster PS
J Pharmacol Exp Ther; 2003 Oct; 307(1):349-55. PubMed ID: 12954795
[TBL] [Abstract][Full Text] [Related]
11. Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia.
Ikemura T; Schwarze J; Makela M; Kanehiro A; Joetham A; Ohmori K; Gelfand EW
J Pharmacol Exp Ther; 2000 Aug; 294(2):701-6. PubMed ID: 10900250
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions.
van Schalkwyk E; Strydom K; Williams Z; Venter L; Leichtl S; Schmid-Wirlitsch C; Bredenbröker D; Bardin PG
J Allergy Clin Immunol; 2005 Aug; 116(2):292-8. PubMed ID: 16083782
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo.
McCluskie K; Klein U; Linnevers C; Ji YH; Yang A; Husfeld C; Thomas GR
J Pharmacol Exp Ther; 2006 Oct; 319(1):468-76. PubMed ID: 16861399
[TBL] [Abstract][Full Text] [Related]
14. Aspergillus fumigatus antigen exposure results in pulmonary airway resistance in wild-type but not in IL-4 knockout mice.
Kurup VP; Xia JQ; Rickaby DA; Dawson CA; Choi H; Fink JN
Clin Immunol; 1999 Mar; 90(3):404-10. PubMed ID: 10075870
[TBL] [Abstract][Full Text] [Related]
15. Effects of L-arginine and phosphodiesterase-5 inhibitor, sildenafil, on inflammation and airway responsiveness of sensitized BP2 mice.
Al Qadi-Nassar B; Bichon-Laurent F; Portet K; Tramini P; Arnoux B; Michel A
Fundam Clin Pharmacol; 2007 Dec; 21(6):611-20. PubMed ID: 18034662
[TBL] [Abstract][Full Text] [Related]
16. Acetamide-45 inhibited hyperresponsiveness and airway inflammation in mice partly depending on phosphodiesterase activity suppression.
Wang K; Shen HH; Huang HQ; Chen JC; Chen Z
Acta Pharmacol Sin; 2008 Oct; 29(10):1195-201. PubMed ID: 18817624
[TBL] [Abstract][Full Text] [Related]
17. Differential allergy responses to Metarhizium anisopliae fungal component extracts in BALB/c mice.
Ward MD; Chung YJ; Haykal-Coates N; Copeland LB
J Immunotoxicol; 2009 Mar; 6(1):62-73. PubMed ID: 19519164
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs.
Wollin L; Marx D; Wohlsen A; Beume R
J Asthma; 2005 Dec; 42(10):873-8. PubMed ID: 16393727
[TBL] [Abstract][Full Text] [Related]
19. Inhaled carbenoxolone prevents allergic airway inflammation and airway hyperreactivity in a mouse model of asthma.
Ram A; Singh SK; Singh VP; Kumar S; Ghosh B
Int Arch Allergy Immunol; 2009; 149(1):38-46. PubMed ID: 19033731
[TBL] [Abstract][Full Text] [Related]
20. Glutamine preferentially inhibits T-helper type 2 cell-mediated airway inflammation and late airway hyperresponsiveness through the inhibition of cytosolic phospholipase A(2) activity in a murine asthma model.
Ko HM; Kang NI; Kim YS; Lee YM; Jin ZW; Jung YJ; Im SY; Kim JH; Shin YH; Cho BH; Lee HK
Clin Exp Allergy; 2008 Feb; 38(2):357-64. PubMed ID: 18070157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
